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Résumé Abstract
La  recherche  en  nanotechnologie  commence  à  recevoir 
une attention croissante dans les médias et la littérature de 
vulgarisation  scientifique,  mais  les  discussions  sur  les 
espoirs  et  les  craintes  concernant  les  nanotechnologies 
sont  déjà  polarisées  par  des  visions  utopiques  et 
dystopiques.  Par  ailleurs,  certaines  discussions  plus 
modérées se concentrent sur les applications à court terme 
des  nanotechnologies,  ainsi  que  sur  leurs  avantages  et 
désavantages  potentiels.  Cependant,  en  explorant  les 
implications sociales et éthiques des nanotechnologies (ou 
la  nanomédecine,  le  but  du  présent  document), 
d'importantes leçons devraient être tirées des expériences 
dans d'autres domaines. En particulier, les études sur les 
enjeux éthiques, légaux et sociaux (ELSI) de la recherche 
en génétique ont réussi à cartographier un grand nombre 
des questions (et des réponses sociales et politiques) qui 
se  posent  lorsque  de  nouvelles  technologies  sont 
déployées.  Nous  soutenons  que,  pour  la  plupart,  les 
questions  éthiques  et  sociales  qui  se  posent  dans  la 
nanomédecine  ne  sont  pas  tout  à  fait  nouvelles  et  ne 
nécessitent  donc pas de nouveaux principes ou  cadres 
éthiques,  ni  un investissement  massif  dans la  recherche 
« NELSI ». Au lieu de cela, nous avons besoin d'un soutien 
pour le développement d’une culture de l'éthique parmi les 
scientifiques et les cliniciens, des connaisances de base en 
science  et  médicine  pour  les  bioéthiciens  et  une 
compétence  sociale  pour  les  citoyens  pour  qu’ils  peut 
participer activement aux débats sur les répercussions des 
nouvelles technologies en général.
Nanotechnology  research  is  beginning  to  see 
widespread  coverage  in  the  media  and  popular 
science  literatures,  but  discussions  of  hopes  and 
fears about  nanotechnology have already become 
polarised into utopian and dystopian visions.  More 
moderate  discussions  focus  on  the  near-term 
applications  of  nanotechnologies,  and on  potential 
benefits and harms. However, in exploring the social 
and  ethical  implications  of  nanotechnology  (or 
nanomedicine,  the  focus  of  this  paper),  important 
lessons should be learned from experiences in other 
fields. In particular, studies of the ethical, legal, and 
social  issues  (ELSI)  of  genetics  research  have 
successfully mapped out many of  the issues (and 
social and political responses) that arise when new 
technologies are deployed. It is our contention that, 
for  the  most  part,  the  ethical  and  social  issues 
arising in nanomedicine are not altogether new, and 
thus  do  not  require  novel  ethical  principles  or 
frameworks,  nor  a  massive  investment  in  ‘NELSI’ 
research. Instead, what is needed is support for the 
development  of  a  culture  of  ethics amongst 
scientists and clinicians, basic scientific and medical 
knowledge for bioethicists, and a social competency 
for citizens to participate actively in debates about 
the implications of new technologies in general. 
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Introduction 
The  last  decade  has  been  characterized  by  increasing  hype  about  nanotechnology  and 
nanomedicine, often in the form of scientific and governmental exuberance about the potential 
clinical (and economic) benefits. The ability to manipulate materials at the atomic or nanoscale – 
whether they be physical (e.g., metals), chemical (e.g., polymers) or biological (e.g., DNA) in 
nature  –  has  enabled  scientists  to  access  special  properties  associated  with  quantum 
mechanics  (e.g.,  greater  surface  area,  chemical  reactivity)  and  develop  new  materials  or 
systems.  But  the  very  thing  that  makes  nanotechnologies  desirable  can  also  limit  our 
understanding of how these properties may interact with other materials and systems at the 
nano or macro scales. The enthusiam for “all things nano” has thus been matched by mounting 
concern on the part of activists and social commentators about the safety of nanotech-derived 
products and their impact on public health (e.g., pollutans or mutagens), and the potential social 
and ethical issues (e.g., use for enhancement or military applications). Countless stories in the 
print, television, and radio news have both enthused about the possibilities and lamented the 
dangers  of  nanotechnology.  Similarly,  in  the  academic  literature,  health  science  research 
published  in  journals  as  diverse  as  Biomedical  Microdevices [1], Mycopathologia [2], 
Nanotechnology [3], and  BMJ [4]  has pointed to both the potential health benefits and risks 
associated with nanomedicine. On the ethical,  legal,  and social  side, we have seen articles 
published in  Technology Review  [5]  Columbia Science and Technology Law Review [6]  and 
Nanotechnology [7],  and  these  have  focused  more  on  the  particular  challenges  raised  by 
nanomedicine for individuals, institutions and society.
Much like the early debates about genetically modified foods in the late 1990s [8], discussions 
about nanotechnology have also been characterised by utopian and dystopian visions of the 
future  [9-11].  Between  these  extremes,  discussion  has  centred  on  the  impact  that  the 
anticipated breakthroughs in nanoscience and nanotechnology will have upon existing chemical, 
material, biological and information sciences. In the case of biology and medicine, which are the 
focus of this paper, research points towards new means of circumventing problems faced by 
gene therapy and current methods of drug delivery, to name but two examples [12-14] But as is 
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the case with many forms of scientific research and innovation, applications of nanomedicine 
will not be without risks. Nanoparticles may target the wrong cells or interact negatively with the 
body’s  proteins,  enzymes,  or  organs;  worse  yet  would  be  the  uncontrolled  replication  of 
nanoparticles, potentially resulting in leukaemia-like phenomena similar to what has occurred 
with some viral-based gene therapy experiments [15,16]. Beyond the context of human health, 
nanotechnology  innovations  may  raise  concerns  about  the  environment  (e.g.,  risks  of 
widespread  contamination),  regulatory  issues  (e.g.,  regulating  in  a  context  of  significant 
scientific uncertainty about risk), privacy [17] and civil liberties (e.g., potential for low-cost and 
thus pervasive surveillance), military applications (e.g., nanoscale weapons), etc. [18].
In seeking to understand the challenges posed by developments in nanomedicine, we suggest 
that important lessons can and should be learned from research and policy on the ethical, legal, 
and social implications of genetics/genomics research, known as ELSI in the US and GE3LS 
(Genomics, ethics, environment, economic, legal issues) in Canada. As with nanotech, early 
developments in genetics (and then genomics) led to much scientific, policy and media hype, 
which was closely followed by public and academic concerns about health and safety issues, as 
well as social and ethical challenges that needed attention (e.g., stigmatization, discrimination, 
designer  babies).  Two  decades  of  ELSI  research  helped  shape  the  development  and 
implementation of genetic and genomic technologies, resulting in vigorous debate about and the 
production of a plethora of ethical frameworks and public policy on everything from informed 
consent  regarding biobanking [19]  to  the direct-to-consumer marketing  of  genetic  tests  and 
other ‘personalised medicines’ [20]. 
In line with other commentators [21], it is our contention that, for the most part, the socio-ethical 
and  legal  challenges  or  questions  posed by  nanomedicine  are  not  altogether  new or  very 
different from those identified with genetics or genomics technologies. Such being the case, 
they do not necessarily require novel ethical frameworks nor a massive financial investment in 
‘NELSI’  research  because  most  of  the  ethical  principles  or  tools  needed  to  address  the 
challenges  posed  by  nanotechnology  already  exist,  having  been  developed  during  three 
decades  of  ELSI  research.  What  is  needed,  instead,  is  support  for  interdisciplinary 
collaborations  between  applied  (nano)science  and  ELSI  researchers  to  address  problems 
related to nanotech as they arise [22], in order to develop a culture of ethics amongst scientists 
and clinicians, and ensure that bioethicists (and other humanities and social sciences scholars) 
have sufficient understanding of the basics of science and medicine. But it will also be important 
to  help  the  public  develop  a   broader  public  or  social  competency  –  i.e.,  basic  scientific 
knowledge and critical thinking skills – so that citizens can be equiped to engage with debates 
about the implications of new technologies in general. 
Lessons from the World of Biotechnology and Genetic Engineering
Well  before  the  completion  of  the  Human  Genome Project  in  2003,  a  substantial  body  of 
academic and policy literature had developed, replete with stories of hope, hype, and fear about 
the near term benefits and harms of genetics and genomics research. Within a decade, it was 
promised, genetic testing and gene therapy would cure both rare and common diseases, and 
pharmacogenomics (i.e.,  understanding the influence of genetic variation on drug response) 
would revolutionise pharmaceutical development, drug delivery, and usher in a future of cost-
effective personalised medicine [23,24]. But these hopes have proven premature. Gene therapy 
research,  while  showing  some  promise  in  the  development  of  safe  and  effective  delivery 
mechanisms,  has  been  marred  by  very  public  setbacks  including  the  deaths  of  research 
subjects  [25],  while  in  the  case  of  pharmacogenomics,  even  putative  exemplars  of  the 
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technology  (e.g.,  Herceptin  and  Abacavir)  have  been  of  limited  efficacy  [26,27].  Cautious 
evaluations  suggest  that  while  there  may  eventually  be  practical  applications  of  these 
technologies, they are unlikely to be ‘just around the corner’ [28]. More vocal opponents argue 
that the public has been misled, and that the primary goals of massive government investments 
in the Human Genome Project and biotechnology had more to do with supporting ‘big science’ 
in pursuit of economic development and the creation of ‘knowledge-based economies’, than with 
improving human health [29]. This is not to say that genetics research is a hopeless endeavour, 
only  that  the  development  of  practical  applications  will  take  longer,  and  be  much  less 
predictable, than was initially promised [30].
It appears that with nanotechnology, history is to some extent repeating itself. The pattern of 
two-lane hype – glowing scientific optimism coupled with strident social criticism – is strikingly 
similar to the pattern so recently observed in relation to biotechnology [31]. However, hype has 
its upside and its downside. While hype may be crucial for attracting initial research funding and 
sustaining scientific, government and public support, if overdone, hype can create unrealistic 
expectations that could lead to a loss of public trust [32-34]. However, empirical research is still  
needed to see whether this loss of trust actually occurs in practice, and with which technologies 
[35]. Similarly, over-sensitivity to or disproportionate concern about particular technologies can 
lead to their implementation being significantly delayed or unduly constrained. A case in point 
was the focus on the human safety issues with GMO foods, which received considerable public 
attention despite a lack of scientific evidence to substantiate such risks. The misguided focus on 
human health and the related debate over the labelling of GM foods arguably shifted public 
attention away from more plausible concerns related to the environmental impact of GM crops 
[36].  In a context  where there is  significant  scientific  uncertainty  about  the safety  of  a new 
innotvation, a precautionary approach is fully justified and warranted to ensure the protection of 
public health and security. Our point, here, is that an overly hyped or polarised public debate 
about a class of technologies – such as GMOs, or for our purposes, nanotech – can lead to an 
entire  sector  being inappropriately  “painted with  the same brush”,  thereby  undermining the 
deployment of certain beneficial and safe innovations while also minimizing regulatory controls 
for those innovations that are clearly problematic.
 
The  events  of  the  last  two  decades  –  with  ‘hyped’ biotech  and  genetic  innovations  being 
accompanied by substantial  public  and academic debate over  associated ethical,  legal  and 
social implications – are, we suggest, being repeated in the case of nanotechnology. Putting 
aside the more extreme concerns about environmental disaster, expressed most dramatically by 
Prince Charles’ fear of self-replicating nanorobots running amok and leading to a world overrun 
with  “grey  goo”  [37],  there  are  legitimate  questions  about  the  safety  of  some  nanotech 
developments (including questions about pollution and toxicity) because of scientific uncertainy 
about how nanoparticules interact with biological systems (e.g., human lungs). But while the 
particular properties and behaviour of nanoparticles clearly require scientific study in order to 
determine when and how they might be toxic and thus in need of control (e.g., health and safety 
regulations), this does not mean that an entirely new field of environmental or health sciences is 
required with completely new tools or infrastructure. Like early reflections on the ethical, legal 
and  social  implications  (ELSI)  of  genetic  technologies,  initial  work  on  the  ethics  of 
nanotechnology  seems  to  assume that  ‘this  stuff  is  radically  new,’  requiring  a  ‘new ethics’ 
because the existing ethical or conceptual tools are insufficient [38]. The difference, however, is 
that  nanotech  ethics,  or  NELSI,  is  developing  in  a  context  where  there  is  already  a  well 
established field of research, i.e., ELSI. It is in important, then, for NELSI researchers to be 
modest in their calls for support and attention to issues of legitimate concern in nanotech, and 
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not  to  oversell  their  speciality  as  if  it  is  an  entirely  new  field,  in  need  of  completely  new 
resources.
More Smoke than Fire?
Developments  in  genetics  and  biotechnology  in  the  1980s  and  1990s  led  to  substantial 
international political, academic, and financial investment (US$100 million invested by the US 
government  alone)  in  ELSI  research  [39].  Faced  with  novel  technologies  and  medical 
procedures such as predictive testing for late-onset conditions, genetic testing for characteristics 
and for variations between population groups, and embryonic procedures, it was deemed critical 
to also consider the range of attendant social and ethical questions [40]. Indeed, ELSI research 
has  gone  a  long  way  toward  addressing  many  of  these  questions  and  supporting  the 
implementation of national and international policies and regulations to minimize and control 
potential harms. For example, international and professional moratoria have been implemented 
to protect against unjust discrimination in the use of genetic testing for health or life insurance 
[20,41],  and  to  prevent  the  genetic  modification  of  germ-line  tissues  in  face  of  the  grave 
misgivings  concerning  the  genetic  engineering  of  future  generations  [42].  These  moves 
arguably  resulted  in  large  part  from  a  willingness  of  researchers  to  engage  in  multi-  or 
interdisciplinary discussions, and so one of the real accomplishments of ELSI has been to bring 
together diverse research communities. However, ELSI research has also been criticized for 
being  complacent  about  (if  not  complicit  in)  dominant  social  and  political  ideologies,  and 
insufficiently responsive to public concerns and the need for greater democratic involvement 
[29,43]. Further, the focus of much ELSI research has been on the implications of a narrow 
group of technologies (e.g., genetic tests, new reproductive technologies, stem cell research) 
[44] and so has not given adequate consideration to the larger social and political contexts in 
which these technologies manifest [45].
In light of both the strengths and weaknesses of ELSI, we should be cautious about calls for 
similar  large-scale  public  investment  in  nanotechnology  ethics,  such  as  the  US  ‘NELSI’ 
programme, or as Mnyusiwalla, Daar and Singer propose for the Canadian context, ‘NE3LS’, the 
study of nanotechnology’s ethical, environmental, economic, legal, and social implications [7]. 
According to these authors, “what is worrying…is that the serious study of NE3LS research lags 
far behind the science. Despite availability of research funds, NE3LS research has not yet been 
taken seriously and pursued on a large enough scale” [7, p. R9]. This concern, however, seems 
to play on the naïve view that science and technology develop in a vacuum, outside existing 
social, ethical and political discourses; and thus according to Mnyusiwalla et al, nanotechnology 
can  be  seen  to  ‘race  ahead’ of  the  ethics  because  the  ‘ethical  issues’ are  specific  to  the 
individual technology in question. Yet, as has been clearly demonstrated in the science and 
technology studies literature, technologies are invariably developed within and responsive to the 
larger social, political and cultural contexts, including socio-ethical  debate [46-48]. We agree 
with Mnyusiwalla et al. that nanotechnologies present important social and ethical challenges in 
need of critical study, such as the implications for privacy and civil liberties of the convergence 
between hitherto distinct technologies (telecommunication, computing, optics). Nonetheless, we 
maintain that  many – if  not  most – of the social,  ethical  and legal  concerns related to this 
technology, and in particularly those that relate to novel medicines, are similar to those arising 
with other new biomedical technologies, and for which we already have a set of tried and tested 
ethical tools, including principles and ethics frameworks. 
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Ethics and Nanomedicine
Nanomedicine might be thought to be categorically different from biotechnology because it is 
inherently interconnected to the broader field of nanotechnology, a field that integrates or leads 
to the convergence of  domains as diverse as biology,  material  sciences,  chemistry,  particle 
physics,  public  health  and  environmental  science.  In  other  words,  the  socio-ethical  issues 
associated  with  nanomedicine  will  necessarily  include  considerations  of  public  health, 
environmental impact, and so on. However, even brief reflection on the issues posed by gene 
therapies or other forms of genetic engineering demonstrate that biotechnologies can also have 
socio-ethical and legal implications that extend beyond the strictly medical realm to concerns 
about public health or environmental ethics (e.g., risk of epidemics through the introduction of 
animal pathogens into the human population).
To be sure, nanomedicine offers many exciting new possibilities and poses numerous significant 
socio-ethical  challenges.  There  will,  for  example,  be  concerns  related  to  constraints  on 
experimentation on human research subjects that will pose very real challenges for research 
ethics committees,  health policy  makers and regulators.  As noted above,  both benefits  and 
harms may result from the introduction of nanoparticles into the human body. As is the case with 
all  forms of technological innovation, some ‘skilling-up’ to learn about the basic science and 
applications  of  nanomedicine  will  be  needed  for  proper/adequate  oversight  and  associated 
regulatory initiatives, and there could plausibly be legal and safety considerations particular to 
nanomedicine. Yet, the simple fact that the technology is different does not mean that the ethical 
challenges raised by such research,  or  the principles  that  must  govern the ethical  or  legal 
treatment of human research participants, will  differ. Whether the technology in question is a 
gene therapy, a genetic test, a pharmaceutical, or a nano-enhanced version of one of these, its 
testing on human research participants will  still  be subject to standard review procedures to 
ensure their free and informed consent, safety, and so on. [49]. 
To begin with, following pre-clinical  animal testing that demonstrated potential  effectiveness, 
research ethics review (based on principles of safety, efficacy, informed consent, and so on) 
would be required before proceeding to Phase I and Phase 2 clinical trials on humans. Similarly, 
in commercial contexts, the marketing of nanotechnologies will  raise issues familiar to those 
who study organisational, business, or technology ethics. Concerns may be raised here with 
regards to patentability,  product  safety, or the social  responsibility  of nanotech companies – 
concerns  reminiscent  of  those  studied  in  the  context  of  the  biotech  and  pharmaceutical 
industries [49].  Thus novel scientific  or  clinical  developments do not  necessarily bring novel 
ethical considerations. While there may well be challenging applications of ethical precepts that 
warrant  careful  ethical  consideration,  new  developments  do  not  in  general  necessitate  the 
articulation of entirely new ethical principles.
Keeping abreast of the latest clinical developments is a professional responsibility for medical 
practitioners. What will the arrival of radically new nanomedicines mean for them? We conclude 
this section with a note to the practicing physician, whose busy clinical life may seem like it is on 
the verge of being swamped by yet another technological revolution. It has been noted that 
practicing  clinicians  have  faced  substantial  obstacles  in  incorporating  the  fruits  of  genetic 
science into their practices [50]. The (apparently) imminent arrival of nanomedicine may seem 
like an impending catastrophic burden on the time that the average physician can allocate to 
continuing education. Will the coming of nanomedicine imply a vast range of new technical skills 
and ethical issues for the practicing physician to master? The happy answer, here, is ‘no’. For 
the most part, nanomedicine will likely involve incremental (if sometimes striking) changes in the 
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way clinical medicine is currently practiced. Nanomedicine may well bring about new ways to 
deliver drugs, new ways to rebuild damaged tissues, and new ways to detect pathogens and 
toxins. But nanomedicine will not fundatemally change what it means to be a physician, nor will 
it change the fundamental principles of medical ethics.
Do We Need ‘NELSI’?
In light of the above critique, we believe that the first grants handed out to researchers seeking 
to study NELSI (such as two US$1 million grants from the US National Science Foundation, 
given to  two researchers  [51])  have repeated the mistakes made by many of  the  granting 
organisations that funded ELSI research. In both the biotech and the nanotech cases, granting 
agencies – particularly those whose primary focus is on science – failed to see the differences 
between research in, say, the development of nanomedicine itself, and research into the ethical 
implications of nanomedicine. In the former case, giving out a few large grants to highly capable 
teams may  be  an  excellent  way to  produce  results.  In  the  latter  case,  it  is  not.  Providing 
substantial dedicated funding for ethics projects about ‘big science’ (e.g., US ELSI or Canadian 
GE3LS) has clearly stimulated collaboration, built capacity, led to more diverse research related 
to  the  way  the  science  and  biotechnology  are  integrated  into  society,  and  revealed  the 
problematic nature of scientific and technological institutions [43,45]. Nevertheless, we suggest 
that in the case of research on the socio-ethical and legal implications of nanomedicine, what is 
needed now is more funding to support existing (and to stimulate new) multidisciplinary and 
interdisciplinary collaborative networks, alongside a broad range of smaller research projects 
that  encourage diverse and divergent  perspectives and socio-ethical  analyses [22].  Funding 
agencies ought not to place all of their analytical eggs into only a few baskets; instead, they 
should support a wide diversity of researchers from the bioethics community to help map actual 
and emerging NELSI in order that scientists, regulators and civil  society can be equipped to 
prevent the most problematic situations, and manage appropriately the introduction of beneficial 
nanotech.
The rapid  advance of  new technologies of  all  kinds,  and their  rapid  integration into clinical 
practice,  clearly  demonstrate  the  need  for  detailed  social  science  and  empirical  bioethics 
research  to  investigate  the  particular  social  and  technical  details  and  contexts  in  which 
nanotechnology  will  develop  [52].  But  this  does  not imply  the  need  for  multi-million  dollar 
research  projects  focusing  on  ethical  nuances  of  particular  technologies.  To  return  then  to 
Mnyusiwalla  et al.’s  call  for increased research and funding of NE3LS or NELSI, if  they are 
understood (which we believe they ought to be) as calling not for a repeat of ‘big team’ ethics 
research  into  particular  technologies,  but  instead  as  calling  for  support  of  a  broader 
multidisciplinary discussion and capacity development, then we would agree with this aspect of 
their proposal. We would go a step further, however, and argue for funding directed towards the 
development  of  a  broad  social  competency  to  deal  with  the  ethical  implications  of  new 
technologies in general.  Funding programs exclusive to one technology or discipline, such as 
research premised on the notion of ‘genetic exceptionalism,’ would not yield comprehensive 
approaches  to  technology  adaptation  nor  win  broad  support.  In  this  regard,  we  make  the 
following suggestions:
1. Ethics should be an integral part of the education and mentoring of young scientists and 
clinicians. We here join the chorus of scholars and educators calling for the creation of a 
culture of ethics in science [53]. Exactly how to create such a culture is a difficult – and 
researchable – question [54].  It is also an excellent question for funding by research 
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councils  interested  in  dealing  effectively  with  the  ethical  implications  of  novel 
technologies of all kinds.
2. Our  universities  and  public  regulatory  bodies  need  to  do  more  to  produce  social 
scientists, philosophers, legal scholars, and policy-developers with a reasonable degree 
of understanding of science and medicine. Most of those currently engaged in examining 
the ELSI of biotechnologies, for example, had to learn late in life the science needed to 
understand the intricacies of  genetic testing or  stem cell  research.  Granting councils 
should  therefore  make resources and opportunities available  for  teams dedicated to 
developing  cross-disciplinary  competency,  and  to  research  projects  dedicated  to 
determining suitable  curricula  for  producing scientifically  savvy humanists  and social 
scientists.
3. We need to do better at educating and engaging the general public on issues related to 
the social and ethical implications of new technologies. How to do this is of course not 
an easy question,  and the need for dialogue should not  be mistaken for  a need for 
persuasion [55,56]. Some will inevitably argue that the public’s deficit in terms of their 
understanding of science is so severe that our proposal implies a Herculean effort. This, 
we  think,  is  a  mistaken  supposition.  The  average  university  undergraduate  can  be 
taught, in just minutes, enough about the basic science of somatic cell nuclear transfer, 
for example, to allow him or her to arrive at informed opinions on the various arguments 
offered in relation to the ethics of human cloning. If the public is to be engaged, what we 
should  be  striving  for  is  not  perfect  public  understanding  in  pursuit  of  total  public 
participation, but rather  sufficient public understanding in pursuit of  meaningful public 
participation. This, too, is a researchable – and fundable – challenge [57].
Conclusion
New, paradigm-bending technologies such as nanomedicine always present choices, and there 
are clearly important social and ethical concerns raised by developments in nanotechnology. We 
must  take  seriously  the  utopian/dystopian  extremes  because  they  set  out  the  poles  of  the 
debate, while also reflecting to some extent the concerns of the general public. Detailed ethical 
analysis and social scientific critique will be needed of the near-term practical applications of 
nanotechnology [52]. But it is our contention that, in most cases, it  is the specific context or 
details of the technology in question that differ (genetics, pharmaceuticals, nanotech), and not 
the substance of the ethical implications inherent with biomedical innovation [21]. For whether 
the particular technology at hand is biotechnology or nanotechnology or information technology, 
the over-arching questions are largely the same [58]. Who will be harmed, and who will benefit? 
Are the gains and losses likely to be shared equitably? How will this new technology affect us as 
people,  and as a community?  Addressing these questions will  help to indicate whether any 
policy improvisation or new regulations are called for. 
We need a combination of  ethically  thoughtful  scientists  and policy-developers,  scientifically 
savvy academics in the social sciences and humanities, and a public with sufficient scientific 
literacy to participate, in an informed way, in what is sure to be an on-going set of debates about 
the role of  science and technology in  our  individual  and collective  lives.  Caution – but  not 
cynicism – is required in discussions about the hopes for and fears of nanotechnology, and this 
should be part of a more robust social competency for grappling with the social and ethical 
issues related to novel technologies of all kinds.
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